PMID: 9166498Jan 1, 1996Paper

High-dose cisplatin as neoadjuvant organ-preserving chemotherapy for squamous cell carcinoma of the larynx

The Cancer Journal From Scientific American
J A LacavaC T Vallejo

Abstract

We conducted this study to evaluate the efficacy and toxicity of fractionated high-dose cisplatin as neoadjuvant organ-preserving chemotherapy, followed by definitive radiotherapy, for untreated and advanced squamous cell carcinoma of the larynx. From August 1990 to April 1994, 32 patients bearing previously untreated advanced squamous cell carcinoma of the larynx (12 stage III and 20 stage IV) received three courses of high-dose cisplatin (100 mg/m2 on day 1 and day 8 every 28 days) before definitive external radiation therapy with 65 to 70 Gy (180-200 cGy daily for 6-8 weeks). Twenty-eight patients were men; median age was 57 years (range, 31-69); and median performance status (ECOG) was 1 (0-2). With an average follow-up time of 18 months (range, 6-47), 30 patients are evaluable for response and 32 for toxicity. Responses after three courses of chemotherapy were: complete response, 18 patients (60%), and partial response, 7 patients (23%), for an overall response rate of 83%. Only one patient showed progressive disease. Fifteen patients (50%; 12 complete and 3 partial responders) had pathologic complete remission. Eighty percent of patients had no evidence of disease after the therapeutic program. Median disease-free surviva...Continue Reading

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.